-
AJOVY may give your patients more migraine-free days vs placebo.1
Select the data:
-
AJOVY may help patients reduce migraine by 50% or more.1
Select the data:
With AJOVY, patients may experience significantly
more migraine-free days vs placebo1
REDUCTION IN MONTHLY HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (PRIMARY ENDPOINT)1,2

REDUCTION IN MONTHLY MIGRAINE DAYS (PRIMARY ENDPOINT)1,2

Patients with chronic and episodic migraine receiving AJOVY had a significant reduction in the use of acute medication vs placebo (secondary endpoint)1,2‡
‡ Reduction of acute medication use (secondary endpoint): Patients in the chronic migraine trial with a mean baseline of 13.1 days for both monthly and quarterly dosing and 13.0 days for placebo saw a mean reduction of: 4.2 days for monthly dosing, 3.7 days for quarterly dosing vs 1.9 days with placebo, P<0.001. Patients in the episodic migraine trial with a mean baseline of 7.7 days for monthly dosing, 7.8 days for quarterly dosing, and 7.7 days for placebo saw a mean reduction of: 3.0 days for monthly dosing, 2.9 days for quarterly dosing vs 1.6 days with placebo, P<0.001.1,2
AJOVY may help reduce migraine days by 50% or more1
PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (SECONDARY ENDPOINT)1

1 in 5 patients with chronic migraine experienced a 75% reduction in monthly average headache days vs 1 in 10 with placebo (post hoc analysis)2†
PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE MIGRAINE DAYS (SECONDARY ENDPOINT)1

1 in 4 patients with episodic migraine experienced a 75% reduction in monthly average migraine days vs ~1 in 7 with placebo (post hoc analysis)2†
†For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.